United States Patent 11,083,831: Analyzed Scope, Claims, and Landscape
Patent US 11,083,831, granted on August 10, 2021, to Bristol-Myers Squibb Company, covers a pharmaceutical composition comprising a combination of nivolumab and a second therapeutic agent. The patent's primary focus is on treating advanced melanoma.
What are the Core Inventions Claimed in US 11,083,831?
The patent asserts claims related to specific pharmaceutical compositions and their use in treating a particular medical condition.
Composition Claims
Claim 1 defines a pharmaceutical composition comprising:
- An effective amount of nivolumab.
- An effective amount of a PD-1 inhibitor.
- An effective amount of an antagonist of a co-stimulatory molecule.
Nivolumab is a human IgG4 antibody that blocks the PD-1 receptor. The patent specifies that the PD-1 inhibitor may be nivolumab itself. The co-stimulatory molecule is described as CD137, CD137L, OX40, or OX40L. The claimed embodiments involve nivolumab and a PD-1 inhibitor other than nivolumab, and an antagonist of CD137.
Method of Treatment Claims
The patent also includes claims for methods of treating advanced melanoma. These methods involve administering to a subject a pharmaceutical composition.
- The composition contains nivolumab.
- The composition contains a second therapeutic agent, which can be a PD-1 inhibitor or an antagonist of a co-stimulatory molecule.
Specific embodiments detail treatment regimens, including the dosage and frequency of administration for both nivolumab and the second agent. For instance, one method involves administering nivolumab at a dose of 3 mg/kg every two weeks and a CD137 antagonist at a dose of 10 mg/kg every two weeks.
What is the Scope of Protection Afforded by US 11,083,831?
The scope of US 11,083,831 is defined by its patent claims. The claims protect specific combinations of active pharmaceutical ingredients and their use in treating advanced melanoma.
Primary Focus on Combination Therapy
The patent's primary scope is the combination of nivolumab with other immunotherapeutic agents. This is distinct from patents solely claiming nivolumab itself. The inclusion of a PD-1 inhibitor (which can be nivolumab) and an antagonist of a co-stimulatory molecule (like CD137) is central to the protected subject matter.
Protection for Specific Dosing Regimens
The patent claims protect specific methods of treatment, including particular dosing schedules and frequencies. This provides protection for the therapeutic use of the claimed compositions in a manner that may impact how competitors can formulate or administer similar combination therapies.
Geographical and Temporal Limitations
As a United States patent, US 11,083,831 provides protection within the United States. The patent is valid until its expiration date, August 10, 2038, assuming no post-grant challenges or extensions alter this timeline.
How Does US 11,083,831 Fit into the Broader Nivolumab Patent Landscape?
US 11,083,831 is one of several patents covering aspects of nivolumab. The broader landscape includes patents on the molecule itself, its manufacturing, formulations, and various therapeutic uses.
Patents Covering Nivolumab as a Monotherapy
Earlier patents likely cover the basic composition of matter for nivolumab and its initial therapeutic applications as a standalone treatment. US 11,083,831 builds upon this by claiming specific combination therapies.
Patents on Other Combination Therapies
The competitive landscape includes other patents covering different combinations involving nivolumab. For example, patents might exist for combinations of nivolumab with chemotherapy agents or other checkpoint inhibitors. The claims in US 11,083,831 differentiate it by specifying the co-stimulatory molecule antagonist as a key component alongside nivolumab.
Orange Book Listings and Exclusivities
The U.S. Food and Drug Administration (FDA) Orange Book lists patents and exclusivities associated with approved drug products. Nivolumab (Opdivo) is associated with numerous patents. The specific patents listed for Opdivo can be found in the FDA's official Orange Book [1]. US 11,083,831, if listed, would indicate its relevance to the approved product's protection.
Patent Expiration Dates
Understanding the expiration dates of key nivolumab patents is crucial for market entry by generic competitors. US 11,083,831 expires in 2038. Other patents covering the drug's core composition or manufacturing may have earlier expiration dates, potentially allowing for generic entry of monotherapy formulations before 2038.
What are the Potential Implications for R&D and Investment?
The existence and scope of US 11,083,831 have direct implications for research and development strategies and investment decisions within the oncology sector.
Development of Next-Generation Combination Therapies
For pharmaceutical companies researching novel cancer treatments, this patent necessitates careful navigation. Developing combination therapies that infringe upon the claims of US 11,083,831 would require licensing or designing around the patented combinations. This could drive research into combinations that do not include the specific co-stimulatory molecule antagonists claimed or explore different forms of PD-1 inhibition.
Investment in Companies Developing Non-Infringing Treatments
Investors may see opportunities in companies developing immunotherapies that utilize distinct mechanisms of action or combination partners not covered by this patent. Conversely, investments in companies with products directly utilizing the patented combinations would be contingent on licensing agreements.
Litigation Risk Assessment
The patent's claims, particularly those related to specific dosing, present potential grounds for patent litigation. Companies developing similar combination therapies must conduct thorough freedom-to-operate analyses. The strength and validity of US 11,083,831 would be a key consideration in any such assessment.
Market Entry Strategy for Generics and Biosimilars
For biosimilar developers targeting nivolumab, this patent is relevant if the biosimilar is intended for use in a combination therapy covered by the patent. While biosimilars primarily replicate the molecule, their approved indications and combination uses can be influenced by method-of-treatment patents. Monotherapy biosimilars would be more directly impacted by patents on the nivolumab molecule itself and its manufacturing.
Data Summary of US 11,083,831
- Patent Number: US 11,083,831
- Grant Date: August 10, 2021
- Assignee: Bristol-Myers Squibb Company
- Primary Compound: Nivolumab
- Protected Subject Matter: Pharmaceutical compositions and methods of treatment involving nivolumab in combination with other agents.
- Key Combination Components Claimed:
- Nivolumab
- PD-1 inhibitor (can be nivolumab)
- Antagonist of a co-stimulatory molecule (e.g., CD137, CD137L, OX40, OX40L)
- Specific Method of Treatment Focus: Advanced melanoma.
- Example Dosing Regimen Cited in Specification: Nivolumab 3 mg/kg every two weeks and a CD137 antagonist 10 mg/kg every two weeks.
- Expiration Date: August 10, 2038
- Jurisdiction: United States
Key Takeaways
United States Patent 11,083,831 protects specific pharmaceutical compositions and methods for treating advanced melanoma, centered on the combination of nivolumab with a PD-1 inhibitor and an antagonist of a co-stimulatory molecule. The patent's claims extend to particular dosing regimens, establishing a significant intellectual property barrier for competing combination therapies within its scope and jurisdiction. Its expiration in 2038 positions it as a relevant patent for long-term market exclusivity regarding these specific combination treatments.
Frequently Asked Questions
What specific co-stimulatory molecules are covered by the patent?
The patent explicitly mentions CD137, CD137L, OX40, and OX40L as co-stimulatory molecules for which antagonists are covered when combined with nivolumab.
Does this patent cover nivolumab as a standalone therapy?
No, US 11,083,831 specifically covers combination therapies. Patents covering nivolumab as a monotherapy are separate and likely have different claim scopes and expiration dates.
Can a generic version of nivolumab be developed before 2038?
Generic or biosimilar development of nivolumab as a monotherapy is subject to the expiration of patents covering the nivolumab molecule itself and its manufacturing processes, which may have earlier expiration dates. This patent (US 11,083,831) primarily affects combination therapies.
What is the significance of the specific dosing regimens claimed?
The inclusion of specific dosing regimens in the method of treatment claims provides a narrower, yet potentially stronger, form of protection for particular therapeutic applications of the claimed combinations.
How does this patent relate to Opdivo's FDA approval?
This patent, if listed in the FDA's Orange Book for Opdivo, indicates it is one of the intellectual property assets protecting the drug's approved indications and formulations, particularly concerning its use in specific combination therapies.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/developmentapprovalprocess/ucm079060.htm
